Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults and children weighing at least 40 kg with chronic graft-versus-host disease after failure of two or more prior systemic treatment lines.
LAMPGEN ANALYSIS
Why it matters
The CSF-1 receptor antibody adds a treatment for chronic GVHD after multiple systemic therapies have failed.
What research teams should watch
Verify prior therapy failure, record organ-specific baseline scores and coordinate review of lab changes and infusion reactions.
PRIMARY RECORDS